Genetic-testing firm 23andMe was dealt a major blow in its effort to take the company public on Tuesday when its independent directors resigned from the board over what it called CEO Anne Wojcicki's lack of action on the matter.
"After months of work, we have yet to receive from you a fully financed, fully diligenced, actionable proposal that is in the best interests of the non-affiliated shareholders," the seven directors wrote in an open letter to Wojcicki.
